25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Smartwatch and fitness band wearable consumer electronics can passively measure pulse rate from the wrist using photoplethysmography (PPG). Identification of pulse irregularity or variability from these data has the potential to identify atrial fibrillation or atrial flutter (AF, collectively). The rapidly expanding consumer base of these devices allows for detection of undiagnosed AF at scale.

          Methods

          The Apple Heart Study is a prospective, single arm pragmatic study that has enrolled 419,093 participants ( NCT03335800). The primary objective is to measure the proportion of participants with an irregular pulse detected by the Apple Watch (Apple Inc, Cupertino, CA) with AF on subsequent ambulatory ECG patch monitoring. The secondary objectives are to: 1) characterize the concordance of pulse irregularity notification episodes from the Apple Watch with simultaneously recorded ambulatory ECGs; 2) estimate the rate of initial contact with a health care provider within 3 months after notification of pulse irregularity. The study is conducted virtually, with screening, consent and data collection performed electronically from within an accompanying smartphone app. Study visits are performed by telehealth study physicians via video chat through the app, and ambulatory ECG patches are mailed to the participants.

          Conclusions

          The results of this trial will provide initial evidence for the ability of a smartwatch algorithm to identify pulse irregularity and variability which may reflect previously unknown AF. The Apple Heart Study will help provide a foundation for how wearable technology can inform the clinical approach to AF identification and screening. (Am Heart J 2019;207:66–75.)

          Related collections

          Most cited references28

          • Record: found
          • Abstract: not found
          • Article: not found

          Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

            Atrial fibrillation is a strong independent risk factor for stroke. To characterize the efficacy and safety of antithrombotic agents for stroke prevention in patients who have atrial fibrillation, adding 13 recent randomized trials to a previous meta-analysis. Randomized trials identified by using the Cochrane Stroke Group search strategy, 1966 to March 2007, unrestricted by language. All published randomized trials with a mean follow-up of 3 months or longer that tested antithrombotic agents in patients who have nonvalvular atrial fibrillation. Two coauthors independently extracted information regarding interventions; participants; and occurrences of ischemic and hemorrhagic stroke, major extracranial bleeding, and death. Twenty-nine trials included 28,044 participants (mean age, 71 years; mean follow-up, 1.5 years). Compared with the control, adjusted-dose warfarin (6 trials, 2900 participants) and antiplatelet agents (8 trials, 4876 participants) reduced stroke by 64% (95% CI, 49% to 74%) and 22% (CI, 6% to 35%), respectively. Adjusted-dose warfarin was substantially more efficacious than antiplatelet therapy (relative risk reduction, 39% [CI, 22% to 52%]) (12 trials, 12 963 participants). Other randomized comparisons were inconclusive. Absolute increases in major extracranial hemorrhage were small (< or =0.3% per year) on the basis of meta-analysis. Methodological features and quality varied substantially and often were incompletely reported. Adjusted-dose warfarin and antiplatelet agents reduce stroke by approximately 60% and by approximately 20%, respectively, in patients who have atrial fibrillation. Warfarin is substantially more efficacious (by approximately 40%) than antiplatelet therapy. Absolute increases in major extracranial hemorrhage associated with antithrombotic therapy in participants from the trials included in this meta-analysis were less than the absolute reductions in stroke. Judicious use of antithrombotic therapy importantly reduces stroke for most patients who have atrial fibrillation.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

                Bookmark

                Author and article information

                Journal
                0370465
                398
                Am Heart J
                Am Heart J
                American heart journal
                0002-8703
                1097-6744
                25 April 2021
                08 September 2018
                January 2019
                05 May 2021
                : 207
                : 66-75
                Affiliations
                [a ]Center for Digital Health, Stanford University Stanford, CA,
                [b ]VA Palo Alto Health Care System, Palo Alto, CA,
                [c ]Quantitative Sciences Unit, Stanford University, Stanford, CA,
                [d ]Stanford Center for Clinical Research, Stanford University, Stanford, CA,
                [e ]Information Resources and Technology, Stanford University, Stanford, CA,
                [f ]Apple Inc. Cupertino, CA,
                [g ]Lankenau Heart Institute and Jefferson Medical College, Philadelphia, PA,
                [h ]University of Colorado School of Medicine, Denver, CO,
                [i ]Division of Cardiovascular Disease, Cooper Medical School of Rowan University, Camden, NJ,
                [j ] StopAfib.org, American Foundation for Women’s Health, Decatur, TX,
                [k ]Duke Clinical Research Institute, Duke University, Durham, NC,
                [l ]Division of Cardiovascular Medicine, Stanford University, Stanford, CA.
                Author notes
                Reprint requests: Mintu Turakhia, Marco Perez, Stanford Center for Clinical Research, Stanford University, 1070 Arastradero Rd., Palo Alto, CA, 94304. mintu@ 123456stanford.edu
                Article
                NIHMS1680152
                10.1016/j.ahj.2018.09.002
                8099048
                30392584
                5eecc172-73ac-4ff9-a4a8-933b0221f94b

                This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Article

                Cardiovascular Medicine
                Cardiovascular Medicine

                Comments

                Comment on this article